Bintrafusp alfa, a novel bispecific antibody, achieved an objective response rate of 22% in women with recurrent or metastatic cervical cancer in a phase II nonrandomized controlled trial.
The European Commission has approved two new indications for Keytruda (pembrolizumab), an anti-PD-1 therapy, in gynecologic cancers.
